Type I interferon sensing unlocks dormant adipocyte inflammatory potential
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jun 2020 · 1 min read
In brief
In brief
This study reveals that type I interferon signaling activates dormant inflammatory programs in adipocytes, driving obesity-related metabolic dysfunction through glycolysis-dependent mechanisms. The findings demonstrate conserved effects in human adipocytes and suggest adipocyte inflammation plays a larger role in obesity pathogenesis than previously recognized.
Written by the GCMD Library team from the article.
Statements in this article
White adipose tissue inflammation, in part via myeloid cell contribution, is central to obesity pathogenesis.
Activation of the type I interferon/IFNα receptor axis amplifies adipocyte inflammatory vigor and uncovers dormant gene expression patterns resembling inflammatory myeloid cells.
IFNβ-sensing promotes adipocyte glycolysis.
Glycolysis inhibition impedes IFNβ-driven intra-adipocyte inflammation.
Obesity-driven induction of the type I IFN axis and activation of adipocyte IFNAR signaling contributes to obesity-associated pathogenesis in mice.
IFNβ effects are conserved in human adipocytes.
Detection of the type I IFN/IFNAR axis-associated signatures positively correlates with obesity-driven metabolic derangements in humans.
The type I IFN/IFNAR axis regulates unifying inflammatory features in both myeloid cells and adipocytes.
